Cargando…

Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma

Background: Immunotherapy has achieved remarkable success in treating advanced liver cancer. Current evidence shows that most of the available immune checkpoint inhibitor (ICB) treatments are suboptimal, and specific markers are needed for patients regarded as good candidates for immunotherapy. Necr...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, YunZhen, Wu, GuoJing, Qiu, Xin, Luo, Yue, Zou, YiShu, Wei, XueYan, Li, Aimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468751/
https://www.ncbi.nlm.nih.gov/pubmed/36110223
http://dx.doi.org/10.3389/fgene.2022.916024
_version_ 1784788485881724928
author Peng, YunZhen
Wu, GuoJing
Qiu, Xin
Luo, Yue
Zou, YiShu
Wei, XueYan
Li, Aimin
author_facet Peng, YunZhen
Wu, GuoJing
Qiu, Xin
Luo, Yue
Zou, YiShu
Wei, XueYan
Li, Aimin
author_sort Peng, YunZhen
collection PubMed
description Background: Immunotherapy has achieved remarkable success in treating advanced liver cancer. Current evidence shows that most of the available immune checkpoint inhibitor (ICB) treatments are suboptimal, and specific markers are needed for patients regarded as good candidates for immunotherapy. Necroptosis, a type of programmed cell death, plays an important role in hepatocellular carcinoma (HCC) progression and outcome. However, studies on the necroptosis-related lncRNA in HCC are scarce. In this view, the present study investigates the link among necroptosis-related lncRNA, prognosis, immune microenvironment, and immunotherapy response. Methods: Gene transcriptome and clinical data were retrieved from The Cancer Genome Atlas database. Pearson correlation analysis of necroptosis-related genes was performed to identify necroptosis-related lncRNAs. The Wilcoxon method was used to detect differentially expressed genes, and prognostic relevant lncRNAs were obtained by univariate Cox regression analysis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis were utilized to perform functional enrichment analysis. Lasso–Cox stepwise regression analysis was employed to calculate risk score, which was involved in analyzing immune cells infiltration, immune checkpoints expression, and predicting immunotherapeutic efficacy. Quantitative RT-PCR (qRT-PCR) was performed to detect the expression pattern of lncRNA in cell lines. Results: The 10 lncRNAs generated in this study were used to create a prognostic risk model for HCC and group patients into groups based on risk. High-risk patients with HCC have a significantly lower OS rate than low-risk patients. Multivariate Cox regression analysis showed that risk score is an independent risk factor for HCC with high accuracy. Patients in the high-risk group exhibited a weaker immune surveillance and higher expression level of immune checkpoint molecules. In terms of drug resistance, patients in the low-risk group were more sensitive to sorafenib. The OS-related nomogram was constructed to verify the accuracy of our model. Finally, quantitative RT-PCR experiments were used to verify the expression patterns of candidate genes. Conclusion: The lncRNA signature established herein, encompassing 10 necroptosis-related lncRNAs, is valuable for survival prediction and holds promise as prognostic markers for HCC.
format Online
Article
Text
id pubmed-9468751
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94687512022-09-14 Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma Peng, YunZhen Wu, GuoJing Qiu, Xin Luo, Yue Zou, YiShu Wei, XueYan Li, Aimin Front Genet Genetics Background: Immunotherapy has achieved remarkable success in treating advanced liver cancer. Current evidence shows that most of the available immune checkpoint inhibitor (ICB) treatments are suboptimal, and specific markers are needed for patients regarded as good candidates for immunotherapy. Necroptosis, a type of programmed cell death, plays an important role in hepatocellular carcinoma (HCC) progression and outcome. However, studies on the necroptosis-related lncRNA in HCC are scarce. In this view, the present study investigates the link among necroptosis-related lncRNA, prognosis, immune microenvironment, and immunotherapy response. Methods: Gene transcriptome and clinical data were retrieved from The Cancer Genome Atlas database. Pearson correlation analysis of necroptosis-related genes was performed to identify necroptosis-related lncRNAs. The Wilcoxon method was used to detect differentially expressed genes, and prognostic relevant lncRNAs were obtained by univariate Cox regression analysis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis were utilized to perform functional enrichment analysis. Lasso–Cox stepwise regression analysis was employed to calculate risk score, which was involved in analyzing immune cells infiltration, immune checkpoints expression, and predicting immunotherapeutic efficacy. Quantitative RT-PCR (qRT-PCR) was performed to detect the expression pattern of lncRNA in cell lines. Results: The 10 lncRNAs generated in this study were used to create a prognostic risk model for HCC and group patients into groups based on risk. High-risk patients with HCC have a significantly lower OS rate than low-risk patients. Multivariate Cox regression analysis showed that risk score is an independent risk factor for HCC with high accuracy. Patients in the high-risk group exhibited a weaker immune surveillance and higher expression level of immune checkpoint molecules. In terms of drug resistance, patients in the low-risk group were more sensitive to sorafenib. The OS-related nomogram was constructed to verify the accuracy of our model. Finally, quantitative RT-PCR experiments were used to verify the expression patterns of candidate genes. Conclusion: The lncRNA signature established herein, encompassing 10 necroptosis-related lncRNAs, is valuable for survival prediction and holds promise as prognostic markers for HCC. Frontiers Media S.A. 2022-08-30 /pmc/articles/PMC9468751/ /pubmed/36110223 http://dx.doi.org/10.3389/fgene.2022.916024 Text en Copyright © 2022 Peng, Wu, Qiu, Luo, Zou, Wei and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Peng, YunZhen
Wu, GuoJing
Qiu, Xin
Luo, Yue
Zou, YiShu
Wei, XueYan
Li, Aimin
Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title_full Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title_fullStr Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title_full_unstemmed Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title_short Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma
title_sort construction and validation of a necroptosis-related lncrnas prognosis signature of hepatocellular carcinoma
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468751/
https://www.ncbi.nlm.nih.gov/pubmed/36110223
http://dx.doi.org/10.3389/fgene.2022.916024
work_keys_str_mv AT pengyunzhen constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT wuguojing constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT qiuxin constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT luoyue constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT zouyishu constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT weixueyan constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma
AT liaimin constructionandvalidationofanecroptosisrelatedlncrnasprognosissignatureofhepatocellularcarcinoma